Health Care · Pharmaceutical Preparations

MLYS Mineralys Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 193341484 filings
Russell 2000

MLYS at a glance

Mineralys Therapeutics, Inc. (MLYS, SEC CIK 1933414) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as October 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Mineralys Therapeutics, Inc. (MLYS) shares worth $575.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Congleton Jon on September 30, 2026 of 75,000 shares at $25.46 per share.
  • In the last 90 days, MLYS insiders reported 0 open-market purchases ($0) and 4 open-market sales ($5.2M) on Form 4, a net sale of $5.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 4 sells
Net −$5.2M
13F holders
26 funds
$575.6M · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02 · Item 5.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Business section lacks substantive description of core operations or products
  • Reliance on 2026 Proxy Statement for key corporate governance and executive compensation details
  • No disclosure of new products, services, strategic shifts, or geographic expansions this year
  • References Ernst & Young LLP as principal independent auditor for 2026 financial statements
  • Unusual focus on compliance codes and proxy statement incorporation, minimal direct business narrative

Risk Factors

  • Regulatory risk: FDA review pending for lorundrostat NDA submitted December 22, 2025, with no prior approvals or revenue
  • Macroeconomic risk: Global economic volatility and geopolitical conflicts (Ukraine, Israel, Venezuela) may restrict capital availability for operations
  • Supply chain risk: Dependency on third-party CMOs for cGMP-compliant manufacturing scale-up of lorundrostat, potential delays and cost increases
  • Competitive risk: Market acceptance risk due to potential competing products and alternative therapies affecting lorundrostat launch prospects
  • Financial risk: Accumulated deficit $457.2M with net losses $154.7M in 2025; need substantial capital raises risking dilution or restrictive debt covenants

Management Discussion & Analysis

  • No revenue; net loss $154.7M in 2025 vs $177.8M in 2024, improvement of $23.1M
  • R&D expenses $132.0M in 2025 vs $168.6M in 2024, a 21.7% decrease; G&A expenses $38.6M vs $23.8M, a 62.0% increase
  • No segments disclosed; entire focus on lorundrostat development and clinical trials
  • Cash, cash equivalents, and investments $656.6M at year-end 2025; raised $269.6M in Sept 2025, $188.7M in Mar 2025, and $139.6M via ATM offering through Mar 2026
  • Management expects cash to fund operations for at least 12 months; key risk is timing and success of regulatory approval and clinical trial outcomes

AI summary of the MLYS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New debt-servicing risk triggered by June 2026 Loan Agreement, which matures in 2031
  • Secured-collateral risk: lender foreclosure could include substantially all assets and intellectual property
  • Covenant risk: minimum liquidity and future net product revenue tests could accelerate repayment upon breach
  • Tariff risk: lorundrostat imports may face tariffs as high as 100% of imported value
  • Financing risk: inflation and trade-policy uncertainty could make additional capital more costly or dilutive

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales before potential lorundrostat approval
  • Net loss $57.3M vs $36.9M YoY, R&D $22.7M vs $31.5M and G&A $37.4M vs $9.7M
  • Cash, equivalents and investments $624.7M at September 30, 2026, operating cash use $115.1M
  • Capital deployment: $200.0M Tanabe payment, $100.0M Tranche A borrowing, $143.6M equity proceeds
  • Outlook: cash expected to fund operations through commercial launch for at least twelve months, PDUFA date December 22, 2026

AI summary of the MLYS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers quarter ended September 30, 2026 financial results
  • Corporate update may include pipeline, clinical, or operational developments relevant to valuation

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Derek DiRocco, Ph.D. resigning as director effective December 31, 2026
  • Departure not attributed to disagreements with Mineralys or management

Item EX-99.1: Item EX-99.1

  • FDA PDUFA target remains December 22, 2026, making approval timing the key near-term catalyst for lorundrostat
  • Launch-HTN: 46% on 50 mg reached systolic BP below 130 mmHg at Week 12
Filed Oct 29, 2026Full analysis →

Item 1.02: Termination of a Material Definitive Agreement

  • License Agreement termination confirmed, with details incorporated from Item 1.01
  • No material early termination penalties, limiting immediate cash impact

Item 1.01: Entry into a Material Definitive Agreement

  • Mineralys now owns lorundrostat-related patents and know-how previously licensed from Tanabe
  • License termination removes ongoing license framework but preserves Tanabe milestone payment obligations
Filed Oct 19, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded from seven to nine directors with Kristine Peterson and Lonnel Coats joining effective October 19, 2026
  • Peterson joins Audit Committee as a Class I director, term expiring at the 2027 annual meeting

AI summaries of MLYS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MLYS

Don't miss the next MLYS filing

  • Alerts as it files. A push when MLYS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MLYS, by share count.
  • Ask anything. An AI agent that reads every MLYS filing and answers with sources.

MLYS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Peterson KristineAOct 19, 2026-
COATS LONNELAOct 19, 2026-
COATS LONNELAOct 19, 2026-
Peterson KristineAOct 19, 2026-
Congleton JonSellSep 30, 2026$25.46
Slingsby Brian TaylorSellSep 22, 2026$28.81
Warren EricSellSep 21, 2026$28.12
Warren EricMSep 21, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$84.7M-$192.4M-$170.6M
Net Income-$71.9M-$177.8M-$154.7M
Balance Sheet
Total Assets$251.6M$205.9M$661.8M
Equity$241.2M$191.3M$646.7M
ROE-29.8%-93.0%-23.9%
Per Share
EPS$-1.99$-3.66$-2.29
Cash Flow
Operating CF-$81.2M-$166.3M-$142.4M

Source: XBRL data in Mineralys Therapeutics, Inc. (MLYS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MLYS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MLYS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$575.6M
Q2 202628$838.6M
Q1 202629$685.5M
Q4 202526$876.5M
Q3 202525$740.8M
Q2 202527$171.1M
Q1 202523$127.8M
Q4 202414$70.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MLYS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 29, 2026Analysis-
4Oct 20, 2026--
4Oct 20, 2026--
8-KOct 19, 2026Analysis-
4Oct 2, 2026--
4Sep 24, 2026--
4Sep 22, 2026--
4Sep 17, 2026--
4Aug 25, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
10-QAug 11, 2026Analysis
8-KAug 11, 2026Analysis-
4Jul 23, 2026--
4Jul 20, 2026--
4Jul 15, 2026--
4Jul 15, 2026--
4Jul 10, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 12, 2026--

Related Health Care companies

All Health Care →

MLYS SEC filings: frequently asked questions

Are MLYS insiders buying or selling?

In the last 90 days, Mineralys Therapeutics, Inc. (MLYS) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $5.2 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MLYS stock?

As of September 30, 2026, the largest Mineralys Therapeutics, Inc. (MLYS) holders among the 13F filers tracked by SignalX were BlackRock ($155.1 million), Vanguard Capital Management LLC ($74.7 million), State Street Corp ($72.3 million), T. Rowe Price Group ($52.0 million), Bank of America Corp ($32.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in MLYS's latest 10-K?

In the 10-K filed March 12, 2026, Mineralys Therapeutics, Inc. (MLYS) flagged: Regulatory risk: FDA review pending for lorundrostat NDA submitted December 22, 2025, with no prior approvals or revenue. Macroeconomic risk: Global economic volatility and geopolitical conflicts (Ukraine, Israel, Venezuela) may restrict capital availability for operations. (AI summary of the Risk Factors section.)

What did MLYS report in its latest 8-K?

Mineralys Therapeutics, Inc. (MLYS) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Press release covers quarter ended September 30, 2026 financial results.

What are the latest MLYS SEC filings?

Mineralys Therapeutics, Inc. (MLYS) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on October 20, 2026.

What is MLYS's SEC CIK number?

Mineralys Therapeutics, Inc. (MLYS)'s SEC Central Index Key (CIK) is 1933414. EDGAR lists every MLYS filing under that number.

Ask anything about MLYS

The research agent reads MLYS's filings, financials, insider trades and 13F holders, then answers with sources.